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Background and Aims. Arachidonic acid metabolism actively participates in the initiation, climaxing, and resolution phases of
inﬂammation, and its close connection with inﬂammatory bowel diseases has been only recently discovered. We aimed to clar-
ify the role of diﬀerent arachidonic pathways and the interrelationships between them in Crohn’s disease. Methods.S e v e n t e e n
specimens of Crohn’s disease dated between 2003/1/1 and 2005/1/1 were collected and underwent immunohistochemical analyses
with cylcooxygenase 1, cyclooxygenase 2, 5-lipoxygenase, and 15-lipoxygenase-1 antibodies. Results. (1) The spatial distribution
of the three leading enzymes in arachidonic acid pathway—cyclooxygenase 2, 5-lipoxygenase, and 15-lipoxygenase-1—followed
sequential arrangement in Crohn’s ulcer: neutrophils highly expressing 5-lipoxygenase were in the utmost surface which bordered
the band of cyclooxygenase-2 expression that is located just beneath it, and in the lower layers and below the granulation region
were eosinophils carrying 15-lipoxygeanse-1. (2) Cyclooxygenase-2 and 15-Lipoxygenase-1-positive cells formed two barrier-like
structures that possibly inhibited neutrophil inﬁltration. Conclusion. The regulated distribution indicated coordinated interplay
between inﬂammatory cells and parenchymal cells, between arachidonic acid pathways, and between innate and adaptive immu-
nity; and the barrier-like structures indicated protective roles for cyclooxygenase 2 and 15-Lipoxygenase-1 in Crohn’s disease.
Copyright © 2006 Yao Mao et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Crohn’sdisease(CD)isaninﬂammatoryboweldisease(IBD)
characterized by transmural, segmental, and typically granu-
lomatousinﬂammationofthegut,withalternatingremitting
and relapsing phases in its clinical course. It is generally be-
lieved that dysregulated immune response to luminal bacte-
ria plays a causative role in its pathogenesis. New research is
elucidating genetic factors in the development of CD, among
which the discovery of the Nod2 gene is especially exciting
[1, 2]. However, despite these encouraging ﬁndings and the
initial success of antitumor necrosis factor-alpha therapies,
deﬁnitive cure for this disease is still lacking.
Inthemeantime,advancementintheﬁeldofarachidonic
acid metabolism and the rapidly expanding database on the
versatility of cyclooxygenase (COX) and lipoxygenase (LOX)
enzymes both in physiologic and pathologic conditions, and
in particular the two-faced COX2 enzyme, which not only
serves as a sensitive index for acute inﬂammation under var-
iousinﬂammatorycircumstancesandinavarietyofcellsand
tissues, but also has prohealing and antiinﬂammatory func-
tions [3], led us to suspect pivotal roles for COX2 in CD’s
clinical ﬂuctuation between active and inactive phases. Be-
sides, recent research on the lipoxygenase pathway has also
yielded interesting results, including the ﬁnding that lipoxins
may serve as potent “endogenous stop signals” in inﬂamma-
tion in vivo [4, 5]. Along this line, some authors went on to
suggesttheexistenceofaswitchfromproinﬂammatory5-LO
pathway to proresolution 15-LO pathway in arachidonic acid
metabolism as a beneﬁcial counterregulation in inﬂamma-
tion [5]. Most excitingly, recent studies have clearly shown a
close relationship between arachidonic acid metabolism and
intestinal inﬂammation, in which researchers demonstrated
dramatic therapeutic eﬀects of lipoxin analogs on experi-
mental IBD [6, 7]. All of these led to our study on expres-
sions of cycloxygenases and lipoxygenases in CD, an attempt
to clarify speciﬁc components of arachidonic acid pathways
that actually function in CD in vivo, and the interrelation-
ships between them, in the hope that these data would even-
tually result in a better understanding of CD’s pathogenesis
and hence more eﬀective treatments.
MATERIALS AND METHODS
We used specimens randomly chosen from an archival tis-
sue database in Jinling Hospital dated between 2003/1/1 to
2005/1/1 comprising of 17 Crohn’s disease and 11 control2 Mediators of Inﬂammation
intestinal specimens, which had been ﬁxed in 10% buﬀered
formalin and embedded in paraﬃn. The diagnosis of CD
was based on well-rounded consideration of history, endo-
scopic evaluation, histologic ﬁndings, and adjutant labora-
tory tests. The CD specimens were from patients who un-
derwent enteroctomy for CD-associated intestinal ﬁstulas or
other serious complications at the Department of General
Surgery, Jinling Hospital. The anatomic localizations of the
17 Crohn’s lesions were as follows: nine distal ileums, six
ileum-colonanastomoses,andtwocolons.Amongtheeleven
control specimens, ﬁve colon tissues were from uninvolved
resection margin of colectomy in patients of colon cancer
and the six ileum specimens were either obtained by biopsy
of intestinal issues more than 15 centimeters upstream the
ileum ﬁstula or from uninvolved resection margin of ileuc-
tomy in patients of intestinal ﬁstula caused by acute mesen-
teric embolism. The CD patients were between 14 and 56
years of age (mean ± SD, 32.9 ± 12.6y e a r s ) ;8w e r em a l e s
and 9 were females.
Specimens were sliced into 3μms e c t i o n sa n dm o u n t e d
on silane-coated slides. The slides were deparaﬃnized in xy-
lene and dehydrated through graded alcohols. The deparaf-
ﬁnized sections were autoclaved in 10mmol/L of citrate-
buﬀered saline solution (pH 6.0) for 20 minutes for anti-
gen retrieval. Endogenous peroxidase was blocked by plac-
ing sections into 3% hydrogen peroxidase in methanol for 20
minutes. After a rinse in phosphate-buﬀered saline solution
(PBS), nonspeciﬁc binding was blocked for 20 minutes with
4% fetal bovine serum, 0.1% sodium azide, 0.1% Triton X-
100, 0.3mol/L sodium chloride, and 5% nonfat skim milk.
The slides were incubated overnight in a moist chamber at
4◦C with primary COX1 monoclonal antibody, COX2 mon-
oclonal antibody, 5-lipoxygenase polyclonal antiserum, and
15-lipoxygenase-1 polyclonal antiserum (Cayman Chemical,
Ann Arbor, MI, USA) diluted 1 : 200, 1 : 200, 1 : 300, and
1 : 600, respectively, in Common Antibody Diluent (Bio-
Genex,SanRarron,CA,USA).Selectedslideswerealsoincu-
bated with primary CD68, Vimentin, CK-pan, monoclonal
antibodies (Maixin Bio, Fuzhou, China). After 3 rinses in
PBS, the slides were incubated with biotin-conjugated sec-
ondantibody(Maixin Bio,Fuzhou,China)for30minutesat
37◦C. After another 3 rinses, the slides were incubated with
streptavidin-peroxidase (Maixin Bio, Fuzhou, China) for 30
minutes at 37◦C. 3-3’-diaininobenzidine was then applied as
achromogen.Afterrinse,theslideswerecounterstainedwith
Mayer’s hematoxylin, dehydrated, cleared, and coverslipped.
Negative controls were established by replacing primary an-
tibodywiththeaforementionedCommonAntibodyDiluent.
The immunostaining was evaluated independently by
two pathologists blind to the experiment design, analyzing
the intensity, area, and pattern of immunostaining. In pres-
ence of a discrepancy, a consensus was reached after further
evaluation. The staining was graded on a scale of ﬁve grades:
1 = negative; 2 = suspiciously positive; 3 = weakly positive; 4
= moderately positive; 5 = strongly positive.
The SPSS software (SPSS/PC+ 10.0, Chicago, Ill, USA)
and independent-samples T test were used to compare ex-
pressions of the four enzymes in CD’s lesion with those in
control tissues and P values of less than .05 and .01 were con-
sidered statistically signiﬁcant and very signiﬁcant, respec-
tively.
RESULTS
Immunohistochemicalstainingwithanti-COX-1,anti-COX-2,
anti-5-LO,andanti-15-LO-1antibodies
ThemostnotablefeatureofcyclooxygenaseexpressioninCD
specimens was the marked immunostaining of both COX1
and COX2 in Crohn’s ulcer. COX1 was mainly expressed in
microvessels and some ﬁbroblast-like cells in the surface of
the ulcerated region, while COX2 expression was restricted
totheﬁbroblast-likecellsinthesurfaceofCrohn’sulcer.Sub-
sequent immunostaining experiments in serial slides showed
that these COX2-positive cells also expressed Vimentin, but
not CKpan or CD68, so they might be of the mesenchymal
origin. Sporadic COX1 expressions were also seen in endo-
crinecellsinintestinalcryptsandsomeofthelaminapropria
mononuclearcells,whereasintestinalepitheliaalsoexpressed
COX2 to varied degrees. The immunostaining of 5-LO was
by far the strongest among the four enzymes we examined,
which located mainly in inﬁltrating neutrophils, intestinal
epithelia, and in some of the lamina propria mononuclear
cells, submucosal lymphocytes, and so forth; 15-LO-1 ex-
pression was typically detected in eosinophils in intestinal
lamina propria and in Crhon’s ulcer as well as in granuloma.
The quantitative comparison between expression grades
for the four enzymes in CD’s ulcer, CD’s epithelia, and lam-
ina propria and those in control specimens is illustrated by
Figure 1.
SpatialdistributionsofCOX2,5-LO,and
15-LO-1expressionsinCrohn’sulcer
The expressions of the three major enzymes in arachidonic
acidpathwayfollowedspecialspatialarrangement.The5-LO
positive neutrophils were in the utmost surface of the ulcer,
which formed a dark band with clear boundary. Just beneath
it, COX2 positive cells aligned, again forming a band with
clear boundary. Beneath this COX2 band, there was a rela-
tively staining-negative region—granulation tissues consist-
ing of numerous microvessels and lymphocytes, and below
it, a band formed by eosinophils that highly expressed 15-
LO-1 was seen. As shown in Figure 2, the expressions of the
three enzymes roughly formed concentric rings surrounding
the U-shaped ulcer, with 5-LO in the innermost, followed by
COX2, and 15-LO-1 in the outermost ring.
There are several details that are worth noting. Firstly,
both the 5-LO-expressing neutrophil band and COX2 band
had clear boundaries, and the former ended exactly where
the latter started, which strongly suggested an inhibitory
eﬀect of COX2 on neutrophil migration to the ulcer sur-
face, as we could only see thinly scattered neutrophils below
the COX2 band, and almost none within the COX2 band.
Moreover, COX2 band located right between the surface
neutrophils and the microvessel-rich granulation region. AsYao Mao et al 3
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Figure 1: Expression grades for COX1, COX2, 5-LO, and 15-LO-1 in Crohn’s ulcer, Crohn’s epithelia, and lamina propria and control
specimens. (∗∗ P<. 01 compared to control; ∗ P<. 05 compared to control).
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Figure 2: Spatial distributions of COX2, 5-LO, and 15-LO-1 in Crohn’s ulcer. (a) COX2 immunoreactivity in ulcer surface. Note that the
utmost superﬁcial layer was negative for COX2 (magniﬁcations: ×40). (c) COX2 immunoreactivity in ulcer in higher magniﬁcation: ×400.
(b) 5-LO immunoreactivity in ulcer surface. Note the clear border of surface 5-LO-positive neutrophils (magniﬁcations: ×40). (d) 5-LO
immunoreactivity in higher magniﬁcation: ×400. (e) 15-LO-1 immunoreacivity in Crohn’s ulcer, which formed a cuﬀ-like structure around
the U-shaped ulcer. Note that these cells surrounded the granulation region (magniﬁcations: ×40) representative of similar eight.4 Mediators of Inﬂammation
these microvessels were the essential sites for neutrophils re-
cruitment, the COX2 band seemed to have formed a barrier
thateﬀectivelypreventneutrophilmigrationfrombloodves-
sels to the site of acute inﬂammation.
Secondly, below the COX2 band, there were scattered
distributions of 5-LO-positive neutrophils in the vessel-rich
granulation region and regions below, where they joined 15-
LO-1-positive eosinophils. At the same time, 15-LO-1-pos-
itive eosinophils aggregated right below the granulation re-
gion, forming a half-circle surrounding the U-shaped gran-
ulation region (Figure 2(e)). These eosinophils seemed to
form another barrier to prevent neutrophils of the periph-
eralcirculationfrominﬁltratingfurtherintosubmucosaland
subsequent layers of the intestine.
Thirdly,theaforementionedstaining-negativeregionwas
rich in blood vessels and lymphocytes. The existence of nu-
merous lymphocytes in the very adjacency of acute inﬂam-
mation indicates this to be a site for priming of adaptive im-
munityandcrosstalkbetweeninnateandadaptiveimmunity.
DISCUSSION
The spatially sequential distribution of 5-LO, COX2, and 15-
LO-1 expressions from the ulcer surface to layers beneath
coincides with the reported lipid mediator class switching
during acute inﬂammation; in which the authors demon-
strated temporally sequential display of LTB4, PGE2, and
LXA4 in the inﬂammatory exudates in a murine dorsal air
pouch model [5]. As 5-LO, COX2, and 15-LO-1 are the chief
enzymes responsible for LTB4, PGE2, and LXA4 syntheses,
respectively, the spatial sequence of these enzymes could be
translated into spatial sequence of the relevant arachidonic
acid metabolites. But how does this spatial distribution cor-
relate with the temporal sequence? As we know, intestinal
mucosa is the major site where the body encounters foreign
antigensintheformoffoodorluminalbacteria,andsoforth,
soitisthesitewhereinﬂammationinitiatesandtheulcersur-
facerepresentstheinitialphaseofacuteinﬂammation,where
abundant acute inﬂammatory cells—neutrophils—are accu-
mulated. Beneath, however, the general tendency of local-
izing the inﬂammation and healing become manifest, and
represents the chronic and resolution phases of inﬂamma-
tion. And apparently, it takes more time for lipid mediators
from layers beneath to secrete into the lumen as exudates.
Hence, ﬁndings from this study in human CD lesions not
only conﬁrmed results of the previous work in murine air
pouch model, suggesting that lipid mediator class switching
beauniversalmechanismininﬂammation,inrodentsorhu-
man, in intestine or subdermal tissues, but pinpointed the
cell types that generated these lipid mediators as well. In ad-
dition, the much shorter the interval between maximal LTB4
and PGE2 formation and the longer the interval between
maximal PGE2 and LXA4 formation in exudates juxtaposes
perfectly with the spatial distances between corresponding
enzymes in this study.
Another important point is the shared clear bor-
der of 5-LO-positive neutrophil band and COX2-positive
mesenchymalband,andthebarrier-like alignmentofCOX2-
positive cells between neutrophils and the blood-vessel-rich
region below, which strongly indicated the inhibitory eﬀect
of COX2 on neutrophil transendothelial migration from pe-
ripheral blood. While many authors concluded that COX2-
derived PGE2 ampliﬁed acute inﬂammation [3, 5], our
study supported the antiinﬂammatory roles of COX2 and
its metabolites. As could be seen in Figure 2,c o n t r a r yt or e -
sults from ex vivo studies using peripheral neutrophils in
milieu of various agonists, by immunohistochemical meth-
ods, we showed that neutrophils actively participating in
acute inﬂammation did not express COX2. Given the estab-
lished fact that PGE2 is the dominant metabolite of COX2-
mediated pathway, especially in the intestine [8], it is likely
that the observed COX2-positive cells in CD lesion produced
PGE2, which exerted inhibitory eﬀects on migration and
other functions of neutrophils.
There is much evidence supporting COX2’s antiinﬂam-
matory properties. Gilroy and coworkers showed that COX2,
by generating PGE2, might be proinﬂammatory during the
early phase of inﬂammation, but may aid resolution at the
later phase by generating 15deoxyΔ [9–11]P G J 2[ 3]. While
these authors translated their ﬁndings into proinﬂammatory
roles of COX2 and PGE2 in the early phase of inﬂamma-
tion, others pointed to antiinﬂammatory and immunosup-
pressive roles of PGE2 [9, 10, 12–14]. Of special interest is
that COX2 inhibition increased leukocyte adherence to gas-
tric vascular endothelium and COX1 inhibition reduced gas-
tric blood ﬂow [11], which is in agreement with our results.
In an H pylori-induced gastritis murine model, COX1 in-
hibitor SC-560 augmented MPO activity and epithelial cell
apoptosis withreducedPGE2production,whereasCOX2in-
hibitor NS-398 had the same eﬀects without aﬀecting PGE2
production [15]. In other studies, COX2 inhibition or gene
disruption exacerbated inﬂammation-associated colonic in-
jury in experimental colitis [16, 17], and COX2 inhibition
had only limited antiinﬂammatory eﬃcacy in carrageenan-
airpouch inﬂammation [18]. COX2 inhibition can also in-
duce enteropathy [19] and NSAIDs delay gastrointestinal ul-
cer healing [20, 21]. In this study, COX2 expression was de-
tected solely in the superﬁcial region in Crohn’s ulcer with
negligible expression in other intestinal tissues. Together,
thesedataurgeustoseeCOX2inanewlight:theinducedex-
pression of COX2 in inﬂammation should not be interpreted
as its proinﬂammatory nature; on the contrary, its induction
may be a part of a universal mechanism to counterregulate
inﬂammation and promote healing.
The exact mechanism of this inhibitory role of COX2
on neutrophil recruitment is elusive. Serhan and coworkers
showed that PGE2 inhibits LTB4 but mobilizes lipoxin A4
(LXA4) in peripheral blood human PMNs [5], and LXA4
blocks neutrophil migration across postcapillary venules and
inhibits neutrophil entry into inﬂammed tissues in animal
models [22]. Thus it is possible that those COX2-positive
cells produced abundant PGE2, and the latter not only
suppressed LTB4 production but induced LXA4 produc-
tion in neutrophils, and in turn LXA4, with its well-appre-
ciated antiinﬂammatory role [4, 22–25], inhibits neutrophilYao Mao et al 5
migration and exerts other proresolution eﬀects. Indeed, we
observed that the 5-LO expression pattern in surface neu-
trophils was slightly diﬀerent from that in scattered neu-
trophils below the COX2 band—the staining was weaker and
thelobednucleiweresomewhatindistinctinthesurfaceneu-
trophils. We did not observe noticeable 15-LO-1 expression
in these cells; this, however, does not rule out the possibil-
ity that the eicosanoid proﬁle was undergoing a switch from
the powerful chemoattractant leukotrienes to resolution-
promoting lipoxins. It is interesting to mention that we did
ﬁnd 15-LO-1 expression in the necrotized neutrophils in
the intestinal lumen right above the COX2 expression layer.
PGE2 may also inhibit neutrophil migration by other im-
munosuppressive routes, and other COX2 metabolites, espe-
cially PGD2 [26], and even metabolites-independent mecha-
nismsmighthavearole.Butthewell-appreciatedantiinﬂam-
matory 15deoxy Δ [9–11] PGJ2 may not have participated in
this process, because of its lack of eﬀects on neutrophil adhe-
sion and neutrophil-selective chemokine expression [27, 28].
There was a second barrier-like structure formed by 15-
LO-1-expressing eosinophils, located just below the blood-
vessel-rich region, which probably had prevented neu-
trophils from further inﬁltration into intestinal tissues be-
neath. The coexistence of 15-LO-1-expressing eosinophils
and scattered 5-LO-expressing neutrophils strongly indi-
cated interactions of these two cell types in transcellular
biosynthesisoflipoxins,whicheventuallyformedabarricade
against neutrophil inﬁltration. These results showed that the
classical transcellular biosynthetic pathway of lipoxins could
actually take place in Crohn’s ulcers in vivo, and lipoxins
thus formed could be the key factor in limiting neutrophils-
associated injuries in intestines. Recently, evidence of the
dramaticproresolutioneﬀectoflipoxinanalogsandresolvins
is gathering in IBD models, suggesting an excitingly new so-
lution to the challenging problem of IBD treatment [6, 7].
To improve the picture of Crohn’s Ulcer, this piece
of information is added: LTD4 and 5-oxo-ETE, two 5-LO
metabolites, are eosinophil chemoattractants [29]. Thus, the
typical proinﬂammatory 5-LO pathway has its own negative
feedback: by recruiting eosinophils from peripheral blood
and the intestinal submucosa to the inﬂammatory lesion,
transcellularbiosynthesisoflipoxinsandconsequentlycoun-
terregulation of inﬂammation become possible. In addition,
one of the 15-LO products, 15-hydroxyeicosatetraenoic acid
directly inhibits 5-LO [30].
Lastly, the lymphocyte and blood-vessel-rich granulation
regioninCrohn’sulcercouldbethesiteforintimatecrosstalk
between innate immunity and adaptive immunity. COX-
derived eicosanoids, like PGE2, and possibly lipoxygenase-
derived eicosanoids, could modulate lymphocyte’s functions
in a number of ways [31], and thus innate immunity is re-
shaping adaptive immunity. Vice versa, cytokines secreted by
T cells, such as IL-1β, IL-4, IL-10, IFN, TNFα, could up- or
down-regulate COX2 expression [32, 33], and IL-4 and IL-
13 could induce 15-LO expression in macrophages as well
[34–36]. Therefore, it is highly possible that crosstalk be-
tween the two immune systems is ongoing in the granulation
region beneath Crohn’s ulcer surface. PGE2 has a tendency
of biasing the immune system towards Th2 and away from
Th1 respolnses [31], thus dysregulated arachidonic acid
metabolism and suboptimal COX2 induction in inﬂamma-
tion would lead to suppression of Th2 responses and overre-
action of Th1 responses, which might result in CD.
To sum up, this study demonstrated spatial interrelation-
ships between the three leading enzymes in arachidonic acid
metabolism—COX2, 5-LO, and 15-LO-1 in Crohn’s ulcer;
and by combining data from previous works, we described
interactionsbetweendiﬀerentinﬂammatorycellsandarachi-
donic acid pathways, all of which are part of the multistage
inﬂammatory events recognized as Crohn’s ulcer. Our results
indicated protective roles for COX2 and 15-LO-1 in CD and
a new hope for the treatment of CD, namely, by enhancing
COX and 15-lipoxygenase-1-mediated pathwaysand inhibit-
ing 5-lipoxygenase-mediated pathway.
ABBREVIATIONS
CD Crohn’s disease
COX Cyclooxygenase
IBD Inﬂammatory bowel disease
LOX Lipoxygenase
LX Lipoxin
PG Prostaglandin
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